Results 21 to 30 of about 22,949 (256)

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Journal of Diabetes Investigation, 2019
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus.
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku   +7 more
doaj   +1 more source

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study

Drugs in R&D, 2019
Objectives Our objective was to investigate the effectiveness and safety of silodosin in patients with benign prostatic hyperplasia (BPH) who switched to silodosin from another α1 blocker because of inadequate response.
Hiroshi Takahashi, Shinichi Kubono, Takehiko Taneyama, Kiyotoshi Kuramoto, Hideki Mizutani, Noriko Tanaka, Masaki Yoshida   +6 more
doaj   +1 more source

Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance

BMC Psychiatry, 2023
Background A post-marketing surveillance of blonanserin has been ongoing since September 2018. The aim of this study was to assess the effectiveness and safety of oral blonanserin in Chinese young and middle-aged female patients with schizophrenia in ...
Qijing Bo, Xijin Wang, Xuejun Liu, Hong Sang, Zhiyuan Xun, Ruiling Zhang, Xiaodong Yang, Huaili Deng, Keqing Li, Jindong Chen, Meijuan Sun, Guijun Zhao, Xianglai Liu, Duanfang Cai, Guilai Zhan, Juhong Li, Haiyun Li, Gang Wang   +17 more
doaj   +1 more source

Current status, and future prospects of pharmaco-epidemiology and post-marketing surveillance in Saudi Arabia: A review of literature

Saudi Pharmaceutical Journal, 2018
Background: Pharmacoepidemiology is the concept used for evaluating the impact of drugs among a large number of people in the post-marketing phase. The use of this concept makes it increasingly necessary to detect the recurrence of drug-related anomalies
Ashraf El-Metwally
doaj   +1 more source

Post-marketing stability surveillance: Amoxicillin

South African Family Practice, 2006
Background: To ensure the successful treatment of infectious disease using antimicrobial therapy, a sufficient concentration of the stable, active drug is required at the site of infection.
K.K. Naidoo, P. Nompuku, S.N. Mkalali, K. Shabangu, L. Nkabinde, V. Singh   +5 more
doaj   +1 more source

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance

Frontiers in Psychiatry, 2022
Schizophrenia is an unexplained, complex and serious mental illness. Blonanserin (BNS) is a new antipsychotic drug widely used in the treatment of schizophrenia. However, large-scale clinical studies have not been conducted in China.
Haishan Wu, Xijin Wang, Xuejun Liu, Hong Sang, Qijing Bo, Xiaodong Yang, Zhiyuan Xun, Keqing Li, Ruiling Zhang, Meijuan Sun, Duanfang Cai, Huaili Deng, Guijun Zhao, Juhong Li, Xianglai Liu, Guilai Zhan, Jindong Chen   +16 more
doaj   +1 more source

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura   +7 more
wiley   +1 more source

Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study

Pharmaceutics, 2022
Background: The use of immune-modifying biological agents has markedly changed the clinical course and the management of Inflammatory bowel diseases (IBDs).
Martina Tallarico, Caterina Palleria, Livia Ruffolo, Rocco Spagnuolo, Maria Diana Naturale, Adele Emanuela De Francesco, Caterina De Sarro, Rossella Romeo, Rita Citraro, Patrizia Doldo, Ludovico Abenavoli, Luca Gallelli, Francesco Luzza, Antonio Leo, Giovambattista De Sarro   +14 more
doaj   +1 more source

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito, Kamal Benguerba, Ken Tsuchida, Kazushige Yazawa, Isao Tsumiyama, Hiromitsu Kayama, Sandra P. Reyna, Farid Khan, Richard S. Finkel   +8 more
wiley   +1 more source

Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances

Journal of Pharmacological Sciences, 2021
Schizophrenia significantly limits social functioning with positive and negative symptoms and cognitive dysfunction. Blonanserin (LONASEN®), a novel second-generation antipsychotic approved for treating schizophrenia in Japan in 2008, reportedly shows ...
Yoshifumi Inoue, Kimiko Tsuchimori, Hiroshi Nakamura   +2 more
doaj   +1 more source